Assessment of patient-reported measures of bowel function before and after pelvic radiotherapy: an ancillary study of the North Central Cancer Treatment Group study N00CA
- 230 Downloads
The Bowel Function Questionnaire (BFQ) has been used in clinical trials to assess symptoms during and after pelvic radiotherapy (RT). This study evaluated the importance of symptoms in the BFQ from a patient perspective.
Patients reported presence or absence of symptoms and rated importance of symptoms at baseline, 4 weeks after completion of pelvic RT, and 12 and 24 months after RT. The BFQ measured overall quality of life (QOL) and symptoms of nocturnal bowel movements, incontinence, clustering, need for protective clothing, inability to differentiate stool from gas, liquid bowel movements, urgency, cramping, and bleeding. Bowel movement frequency also was recorded. A content validity questionnaire (CVQ) was used to rate symptoms as “not very important,” “moderately unimportant,” “neutral,” “moderately important,” or “very important.”
Most of the 125 participating patients rated all symptoms as moderately or very important. Generally, patients gave similar ratings for symptom importance at all study points, and ratings were independent of whether the patient experienced the symptom. Measures of greatest importance (moderately or very important) at baseline were ability to control bowel movements (94 %), not having to wear protective clothing (90 %), and not having rectal bleeding (94 %). With the exception of need for protective clothing, the presence of a symptom at 4 weeks was associated with significantly worse QOL (P < .01 for all).
The BFQ has excellent content validity. Patients rated most symptoms as moderately or very important, indicating the BFQ is an appropriate tool for symptom assessment during and after pelvic RT.
KeywordsBowel function Content validity Pelvic radiotherapy Quality of life
Bowel function questionnaire
Content validity questionnaire
North Central Cancer Treatment Group
Quality of life
This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported, in part, by Public Health Service grants CA-25224, CA-60276, CA-35101, CA-35103, CA-35415, CA-35431, CA-63849, CA-35269, CA-35119, CA-37417, CA-35267, CA-52654, and CA-35195.
Additional institutions that enrolled patients in this study included: Duluth CCOP, Duluth, MN, USA (Daniel A. Nikcevich, MD); Mayo Clinic, Jacksonville, FL, USA (Kurt A. Jaeckle, MD); Sioux Community Cancer Consortium, Sioux Falls, SD, USA (Miroslaw Mazurczak, MD); Spartanburg Regional Medical Center, Spartanburg, SC, USA (James D. Bearden, III, MD); Meritcare Hospital CCOP, Fargo, ND, USA (Preston D. Steen, MD); Metro-Minnesota Community Clinical Oncology Program, St. Louis Park, MN, USA (Patrick J. Flynn, MD); Carle Cancer Center CCOP, Urbana, IL, USA (Kendrith M. Rowland, Jr, MD); Montana Cancer Consortium, Billings, MT, USA (Benjamin T. Marchello, MD); and Wichita Community Clinical Oncology Program, Wichita, KS, USA (Shaker R. Dakhil, MD).
Conflict of interest
- 1.Kozelsky TF, Meyers GE, Sloan JA, Shanahan TG, Dick SJ, Moore RL et al (2003) North Central Cancer Treatment Group. Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy. J Clin Oncol 21(9):1669–1674PubMedCrossRefGoogle Scholar
- 3.Martenson JA, Bollinger JW, Sloan JA, Novotny PJ, Urias RE, Michalak JC et al (2000) Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol 18(6):1239–1245PubMedGoogle Scholar
- 4.Martenson JA, Halyard MY, Sloan JA, Proulx GM, Miller RC, Deming RL et al (2008) Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol 26(32):5248–5253, Epub 2008 Sep 2PubMedCrossRefGoogle Scholar
- 12.Garcia Compean D, Ramos Jimenez J, Guzman de la Garza F, Saenz C, Maldonado H, Barragan RF et al (1994) Octreotide therapy of large-volume refractory AIDS-associated diarrhea: a randomized controlled trial. AIDS 8(11):1563–1567Google Scholar
- 16.Haddock MG, Sloan JA, Bollinger JW, Soori G, Steen PD, Martenson JA (2007) North Central Cancer Treatment Group. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol 25(10):1255–1259PubMedCrossRefGoogle Scholar
- 23.Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G et al (2007) National Cancer Institute. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clinical trials networks. J Clin Oncol 25(32):5070–5077PubMedCrossRefGoogle Scholar
- 27.Nout RA, van de Poll-Franse LV, Lybeert ML, Warlam-Rodenhuis CC, Jobsen JJ, Mens JW et al (2011) Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 29(13):1692–1700, Epub 2011 Mar 28PubMedCrossRefGoogle Scholar
- 28.Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients: a Dutch colorectal cancer group study. J Clin Oncol 23(25):6199–6206PubMedCrossRefGoogle Scholar